<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02330432</url>
  </required_header>
  <id_info>
    <org_study_id>Pulm/Mw/002</org_study_id>
    <nct_id>NCT02330432</nct_id>
  </id_info>
  <brief_title>Mycobacterium w in Patients With Severe Sepsis</brief_title>
  <acronym>MISS</acronym>
  <official_title>Phase IIb Randomized, Double Blind, Two Arm, Controlled Clinical Trial of Mycobacterium W in Combination With Standard Therapy Versus Standard Therapy Alone in Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pandit Bhagwat Dayal Sharma, PGIMS, Rohtak</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St.John's National Academy of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent evidence suggests that sepsis continuum includes an immune paralytic state, which may
      play a significant role in sepsis. Mycobacterium w by its TLR4 agonist activity may help in
      restoring immunity, thereby improving outcomes in patients with severe sepsis.

      In this randomized trial, the investigators propose to evaluate the efficacy of Mw in
      patients with severe sepsis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>28-day</time_frame>
    <description>28-day all-cause mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New onset organ dysfunction measured by delta SOFA (maximum minus baseline SOFA)</measure>
    <time_frame>28-day</time_frame>
    <description>Measured by delta SOFA (maximum minus baseline SOFA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free days</measure>
    <time_frame>28-day</time_frame>
    <description>Day off the mechanical ventilator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-vasopressor withdrawal</measure>
    <time_frame>28-day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>28-day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>28-day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New-onset infection</measure>
    <time_frame>28-day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Mycobacterium w group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the experimental arm (Mw) in addition to standard care will receive single daily dose of 0.3 mL of Mw (heat-inactivated Mw [0.5 × 10^9]; Cadila Pharma, Ahmedabad, India) in the deltoid region for 3 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best standard care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Best standard care for sepsis</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mycobacterium w</intervention_name>
    <description>Single daily dose of 0.3 mL of Mw (heat-inactivated Mw [0.5 × 10^9]; Immuvac, Cadila Pharma, Ahmedabad, India) in the deltoid region for 3 consecutive days</description>
    <arm_group_label>Mycobacterium w group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best standard care</intervention_name>
    <description>Antibiotics as early as possible; Norepinephrine &gt; vasopressin &gt; epinephrine for hypotension; Blood glucose 140-180 mg/dL; DVT and stress ulcer prophylaxis; Low tidal volume mechanical ventilation; Standard VAP, CLABSI prevention bundles</description>
    <arm_group_label>Mycobacterium w group</arm_group_label>
    <arm_group_label>Best standard care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with severe sepsis within 48 hours of first organ dysfunction

          -  Cardiovascular system dysfunction: systolic blood pressure ≤90 mm Hg or the mean
             arterial pressure ≤70 mm Hg for at least one hour despite adequate fluid resuscitation
             or the use of vasopressors to maintain a systolic blood pressure or mean arterial
             pressure of &gt;90 and &gt;65 mm Hg, respectively

          -  Renal dysfunction: urine output &lt;0.5 ml/kg/hour for two consecutive hours despite
             adequate fluid resuscitation

          -  Respiratory system dysfunction: PaO2/FiO2 ≤300 or ≤250 if lung sepsis

          -  Hematologic dysfunction: platelet count &lt;100,000/mm3 or decrease by 50% in the three
             days preceding enrollment

          -  Unexplained metabolic acidosis: pH ≤7.30

        Exclusion Criteria:

          -  Pregnancy

          -  Gram-positive culture

          -  Only fungal infection as source of sepsis

          -  Patients who received cardiopulmonary resuscitation

          -  Those on immunosuppressive therapy

          -  Those unwilling to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ritesh Agarwal, MD, DM</last_name>
    <phone>2756825</phone>
    <email>riteshpgi@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ashutosh N Aggarwal, MD, DM</last_name>
    <phone>2756824</phone>
    <email>aggarwal.ashutosh@outlook.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Pulmonary Medicine</name>
      <address>
        <city>Chandigarh</city>
        <state>UT</state>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ritesh Agarwal, MD, DM, FCCP</last_name>
      <phone>2756825</phone>
      <email>riteshpgi@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ashutosh N Aggarwal, MD, DM, FCCP</last_name>
      <phone>2756824</phone>
      <email>ashutosh@indiachest.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ritesh Agarwal, MD, DM, FCCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dhruva Chaudhry, MD, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sriram Sampath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <results_reference>
    <citation>Sehgal IS, Agarwal R, Aggarwal AN, Jindal SK. A randomized trial of Mycobacterium w in severe sepsis. J Crit Care. 2015 Feb;30(1):85-9. doi: 10.1016/j.jcrc.2014.08.012. Epub 2014 Aug 28.</citation>
    <PMID>25241089</PMID>
  </results_reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2014</study_first_submitted>
  <study_first_submitted_qc>December 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2015</study_first_posted>
  <last_update_submitted>July 24, 2015</last_update_submitted>
  <last_update_submitted_qc>July 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Postgraduate Institute of Medical Education and Research</investigator_affiliation>
    <investigator_full_name>Ritesh Agarwal</investigator_full_name>
    <investigator_title>Additional Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Mycobacterium Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

